To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Shire's Firazyr

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 12-1 that the efficacy and safety data for Firazyr icatibant from Shire plc (LSE:SHP; NASDAQ:SHPGY) support approval

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE